Spring Bank Pharmaceuticals (SBPH) Short Interest Ratio & Short Volume

Short interest is the volume of Spring Bank Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of October 30th, investors have sold 3,200 shares of SBPH short. 0.02% of Spring Bank Pharmaceuticals' shares are currently sold short. Learn More on Spring Bank Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.02% of Spring Bank Pharmaceuticals' floating shares are currently sold short.

Spring Bank Pharmaceuticals saw a decline in short interest in the month of October. As of October 30th, there was short interest totaling 3,200 shares, a decline of 91.9% from the previous total of 39,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Spring Bank Pharmaceuticals currently has issued a total of 17,267,000 shares. Some of Spring Bank Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Spring Bank Pharmaceuticals currently has a public float of 15,900,000 shares.

0.02% of Spring Bank Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Spring Bank Pharmaceuticals: OptiNose, Inc. (2.76%), Repare Therapeutics Inc. (2.39%), Nuvectis Pharma, Inc. (12.12%), CytomX Therapeutics, Inc. (4.90%), Eliem Therapeutics, Inc. (0.07%), Karyopharm Therapeutics Inc. (19.94%), Citius Pharmaceuticals, Inc. (7.81%), Coya Therapeutics, Inc. (1.53%), FibroGen, Inc. (5.65%), Societal CDMO, Inc. (0.00%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.15 billion), Aon plc ($3.50 billion), Snap Inc. ($3.18 billion), Analog Devices, Inc. ($2.90 billion), The Clorox Company ($2.87 billion), Uber Technologies, Inc. ($2.01 billion), The Kroger Co. ($1.86 billion), International Flavors & Fragrances Inc. ($1.80 billion), Moderna, Inc. ($1.80 billion), and Simon Property Group, Inc. ($1.72 billion). View all of the most shorted stocks.

Short selling SBPH is an investing strategy that aims to generate trading profit from Spring Bank Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Spring Bank Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SBPH, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SBPH, twice per month. The most recent reporting period available is October, 30 2020.